MedTrace Logo

Benefit of IQP-AO-101 for Sleep

NCT03114696 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-01-03

No results posted yet for this study

Summary

The objective of this pilot clinical trial is to evaluate the potential of IQP-AO-101 with respect to sleep-promoting effects in subjects with sleep complaints.

Conditions

  • Insomnia, Nonorganic

Interventions

DIETARY_SUPPLEMENT

IQP-AO-101

1 dose (sachet) to be consumed 30 - 60 mins before bedtime

DIETARY_SUPPLEMENT

Placebo

1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)

Sponsors & Collaborators

  • Analyze & Realize

    collaborator NETWORK

  • InQpharm Group

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2017-09-29
Completion
2017-09-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114696 on ClinicalTrials.gov